Cardiology Trials

 The trial's purpose was to compare rivaroxaban to placebo in patients discharged from the hospital with coronavirus disease 2019 (COVID-19) infection. Design of the Study Participants who were discharged after being infected with COVID-19 were randomly assigned to receive rivaroxaban 10 mg daily (n = 160) or a placebo (n = 160). The total number of enrollees: 320. Follow-up period: 35 days The average patient age was 58 years. 39% of the population was female. Criteria for inclusion: More than the age of 18 COVID-19 infection required hospitalization for at least three days. Thromboprophylaxis at a normal dose Total modified IMPROVE VTE Risk Score 4, or Total modified IMPROVE VTE Risk Score 2 or 3 and D-dimer >500 ng/ml Important Findings: At 35 days, the primary outcome, a composite of symptomatic VTE, VTE-related death, bilateral VTE, symptomatic arterial thromboembolism, myocardial infarction, non-hemorrhagic stroke, major adverse limb event, or cardiovascular death, was 3.1...

 Patients having PCI for acute MI who had completed one month of DAPT with aspirin and ticagrelor without ischemic or bleeding events were randomly assigned to either continue that regimen or switch to aspirin plus clopidogrel for the next 11 months in this study. According to the findings of this trial, among patients undergoing PCI for AMI who had completed 1 month of DAPT with aspirin and ticagrelor without incident, switching to aspirin + clopidogrel for the next 11 months met criteria for noninferiority and superiority compared to continuing with aspirin + ticagrelor. This was mostly due to a decrease in significant bleeding, although ischemia episodes were also reduced quantitatively with a de-escalation technique. De-escalation was carried out without the need for genotype testing or reload. These are intriguing findings that are both therapeutically meaningful and cost-effective. The only limitation is that this trial only involved East Asian patients, therefore its applica...

 The trial's purpose was to compare full revascularization guided by fractional flow reserve (FFR) vs angiography in patients with ST-segment elevation myocardial infarction (STEMI) who underwent PCI of their culprit artery. Design of the Study Patients with non-culprit multivessel coronary disease who underwent initial PCI for STEMI were randomized to FFR-guided revascularization (n = 590) or angiography-guided revascularization (n = 581). The total number of enrollees was 1,171. The duration of the follow-up was 12 months. The average patient age was 63 years. 15% of the population was female. Type 2 diabetes:  18% of the population. Criteria for inclusion: STEMI patients with multivessel non-culprit coronary disease Criteria for exclusion: Single-vessel coronary artery disease Instability of the heart Previously performed coronary artery bypass grafting Calcification of the coronary arteries Chronic complete occlusion Important Findings: At 12 months, the primary outcome of...

 In terms of net adverse clinical events, the MASTER DAPT trial found that shortened antiplatelet medication was not inferior to regular antiplatelet therapy. Description: The trial's purpose was to compare shortened antiplatelet therapy to standard antiplatelet therapy in patients who had percutaneous coronary intervention (PCI) using a biodegradable-polymer sirolimus-eluting stent. Design of the Study:  Participants with symptomatic coronary artery disease who had PCI during the previous 30-44 days were randomly assigned to one of two groups: shortened therapy (n = 2,295) or standard therapy (n = 2,284). Among people who do not require oral anticoagulation: Participants in the abbreviated therapy group promptly discontinued dual antiplatelet therapy (DAPT) and continued single antiplatelet therapy. Participants in the conventional therapy group received DAPT for 5 months before switching to mono antiplatelet medication. Those with an indication for oral anticoagulation inclu...

The LAAOS III trial found that surgical left atrial appendage closure during cardiac surgery was effective when used in conjunction with anticoagulation. Description: The study compared surgical left atrial appendage occlusion to no occlusion in patients with atrial fibrillation who were undergoing open-heart surgery for another reason. Design of the Study: Patients with atrial fibrillation and a high risk of stroke were randomized to surgical left atrial appendage occlusion (n = 2,379) or no left atrial appendage occlusion (n = 2,391) during open-heart surgery for another reason. The total number of students enrolled: 4,770. Follow-up time: 3.8 years. The average patient: 71 years old. 32 percent of the population was female. Diabetes: 32 percent of the population. Criteria for inclusion: People who are having heart surgery with cardiopulmonary bypass. People who have atrial fibrillation and CHA2DS2-Vasc more than 2. Criteria for exclusion: Off-pump surgery  Implantation of a mech...

 The ATLANTIS trial showed that full-dose apixaban is not superior to standard of care (vitamin K antagonist if an indication for OAC; antiplatelets if no indication) among patients undergoing TAVR despite a reduction in valve leaflet thrombosis (compared with antiplatelet therapy ). 

 Among patients with advanced heart failure with reduced ejection fraction (HFrEF), the combination of sacubitril and valsartan was not found to be superior to valsartan in terms of lowering NT-proBNP, and it did not enhance any of the other clinical outcomes studied. The multicenter trial assigned 335 HFrEF patients to one of two treatment groups: sacubitril/valsartan (n=167) or valsartan (n=168). The patients were followed for 24 weeks. EF was less than 20% at baseline, systolic blood pressure was approximately 113 mm Hg, estimated glomerular filtration rate was 63.6 mL/min/1.73m2 in the combination arm and 65.7 mL/min/1.73m2 in the valsartan arm, and NT-proBNP levels were 1,931 pg/ml and 1,818 pg/ml in the respective arms, respectively. The majority of the patients (60 percent) were Caucasian, 60 years old, and almost one-third were female. Because of the significant risk of poor results in this susceptible demographic during the COVID-19 pandemic, the experiment was terminated ...

Therapeutic anticoagulation with COVID-19 infection was not found to be effective in the ACTION study. Design of the Research:  Patients with COVID-19 infection were randomly assigned to either therapeutic (n = 311) or preventive (n = 304) anticoagulation. Rivaroxaban 20 mg was given to stable patients on a daily basis. Enoxaparin 1 mg/kg twice daily was given to unsteady patients. The total number of students enrolled is 615. The follow-up period is 30 days. The average patient is 57 years old. 38 percent of the population is female. Diabetes affects 27% of the population. Criteria for inclusion: COVID-19 infection in patients under the age of 18 D-dimer levels are high. The Most Important Findings: The primary outcome, a hierarchical analysis of mortality, hospitalization, and oxygen usage over the course of 30 days happened in 34.8 percent of the therapeutic anticoagulation group versus 41.3 percent of the prophylactic anticoagulation group (p = nonsignificant). Secondary effect...

 Empagliflozin is better than placebo in improving HF outcomes among patients with symptomatic stable HFpEF on good baseline GDMT, regardless of diabetes status, according to the EMPEROR-Preserved study. The trial's purpose was to see if empagliflozin was safe and effective in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), regardless of diabetes. Design of the Study: Patients were randomly assigned to either empagliflozin 10 mg (n = 2,997) or a placebo (n = 2,991) in a 1:1 ratio. Geographic location, diabetes status, estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction were all used to stratify the experiment (LVEF: more or less than 50 percent ). All of the patients were being treated for heart failure. 11,583 people were screened in total. The total number of students enrolled is 5,988. Follow-up period: 26.2 months (median) The average patient is 72 years old. 45 percent of the population is female. The major outc...

Patients with acute myocardial infarction (MI) received either sacubitril/valsartan or ramipril in this randomized trial, which generated a lot of debate at the American College of Cardiology (ACC.21) about whether the trial was negative (the p-value for the primary endpoint was not statistically significant) or positive (the p-value for the secondary endpoint was statistically significant) (examination of recurrent and not just first heart failure [HF] events was significant).  Criteria for inclusion are as follows: Acute myocardial infarction is the presenting symptom. Left ventricular ejection fraction (LVEF) of less than 40% with or without pulmonary congestion.  Additionally, one of the following conditions must be met:  age less than 70 years,  atrial fibrillation,  estimated glomerular filtration rate (eGFR) less than 60,  diabetes mellitus,  prior MI,  LVEF less than 30%,  Killip class III,  ST-segment elevation MI (STEMI) withou...